New skin pigment drug tested for vitiligo treatment
NCT ID NCT07437560
Summary
This study is testing whether adding an investigational drug called Melanotan II to standard narrowband UV-B light therapy helps restore skin color in adults with stable vitiligo. Sixty participants will receive either the drug or a placebo along with light therapy for 24 weeks. Researchers will measure changes in skin pigmentation, quality of life, and monitor safety to see if the combination treatment works better than light therapy alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONSEGMENTAL VITILIGO are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Shenzhen Hospital
RECRUITINGShenzhen, Guangdong, 518036, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.